Collegium Pharmaceutical (COLL) Cash from Financing Activities (2014 - 2026)
Collegium Pharmaceutical (COLL) posted quarterly Cash from Financing Activities of -$21.3 million for Q1 2026, up 15.43% year-over-year from -$18.5 million in Q1 2025, and up 2.2% quarter-over-quarter from -$21.8 million in Q4 2025.
Collegium Pharmaceutical (COLL) Cash from Financing Activities (2014 - 2026) Analysis & Trends
Collegium Pharmaceutical's Cash from Financing Activities history runs 13 years deep, the most recent figure standing at -$21.3 million for Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 15.43% year-over-year to -$21.3 million; the TTM figure through Mar 2026 stood at -$106.4 million (down 235.57% YoY), while the FY2025 annual figure was -$110.2 million, down 81.91% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at -$21.3 million, up from -$21.8 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $517.8 million in Q1 2022, with the low at -$114.2 million in Q2 2024.
- The 5-year median for Cash from Financing Activities is -$25.8 million (2022), against an average of $6.1 million.
- The sharpest annual moves came in 2022 and 2023: Cash from Financing Activities jumped 4614.86% in 2022, then sank 205.3% in 2023.
- Collegium Pharmaceutical's Cash from Financing Activities stood at -$25.8 million in 2022, then plunged by 162.66% to -$67.8 million in 2023, then surged by 39.14% to -$41.3 million in 2024, then surged by 47.14% to -$21.8 million in 2025, then climbed by 2.2% to -$21.3 million in 2026.
- Business Quant data shows COLL's Cash from Financing Activities at -$21.3 million in Q1 2026, -$21.8 million in Q4 2025, and -$14.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.95 Bn | 39.30 Bn | 2.15 Bn | -1.00 Mn |
| 3 | Zoetis | 31.58 Bn | 29.90 Bn | 1.05 Bn | -813.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -1.13 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 122.40 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -1.24 Bn |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | 63.40 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | -74.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Collegium Pharmaceutical | 887.15 Mn | 737.84 Mn | 110.29 Mn | 292.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 292.09 Mn |
| Jun 30, 2026 | 292.09 Mn |
| Mar 31, 2026 | -21.34 Mn |
| Mar 31, 2026 | -21.34 Mn |
| Dec 31, 2025 | -21.82 Mn |
| Dec 31, 2025 | -21.82 Mn |
| Sep 30, 2025 | -14.82 Mn |
| Sep 30, 2025 | -14.82 Mn |
| Jun 30, 2025 | -48.37 Mn |
| Jun 30, 2025 | -48.37 Mn |
| Mar 31, 2025 | -25.24 Mn |
| Mar 31, 2025 | -25.24 Mn |
| Dec 31, 2024 | -41.28 Mn |
| Dec 31, 2024 | -41.28 Mn |
| Sep 30, 2024 | 149.03 Mn |
| Sep 30, 2024 | 149.03 Mn |
| Jun 30, 2024 | -114.21 Mn |
| Jun 30, 2024 | -114.21 Mn |
| Mar 31, 2024 | -54.15 Mn |
| Mar 31, 2024 | -54.15 Mn |